Anzeige
Mehr »
Mittwoch, 05.08.2026 - Börsentäglich über 12.000 News
China verschärft den Druck - Heavy Rare Earths werden zum geopolitischen Machtinstrument
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
DoPfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
DoYouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort
DoAlnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
DoBooming Dupixent sales fuel Regeneron's biggest quarter since pandemic
DoNew CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
DoBristol Myers delays Cobenfy Alzheimer's psychosis readout again amid another quarterly beat
DoRFK Jr.'s Gardasil litigation ties subject to fresh lawmaker scrutiny after Merck settlement
DoViatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler
29.07.Biogen flips '26 guidance from expected decline to sales increase
29.07.Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026
29.07.Teva's innovation engine offsets generics slump, leaving one analyst 'shocked' by Ajovy's surge
29.07.PMCPA sanctions melatonin drugmaker over misleading information
28.07.How 2 FDA citations complicate Hengrui, Elevar's push for liver cancer combo approval
28.07.With $5.5B settlement offer, J&J could be on its way to resolving talc litigation
28.07.Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution
28.07.GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain
28.07.Havas Lynx revamps New York C-suite 16 months after last shakeup
27.07.FDA approves Otsuka's ADHD drug Simtriyo, teeing up its 'next major CNS launch'
27.07.On 4th try, Outlook Therapeutics scores FDA nod for reformulated version of Roche's Avastin for AMD
27.07.Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter
27.07.AstraZeneca stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss
27.07.Legend Biotech CEO abruptly steps down without permanent replacement
24.07.Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey
24.07.Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback